China's Simcere Reports Slow Q1 Results, But Sales Force Reorganization Could Help Attract New Pharma Partners
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Simcere Pharmaceutical Group, one of the first Chinese domestic pharmaceutical companies to list in the U.S., reported a slow first quarter result due to slower than expected sales of lead product line first-to-market edavarone injection branded Bicun and Yidasheng.
You may also be interested in...
Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research
SHANGHAI - Although anti-infective drugs still dominate China's pharma market with roughly one-fourth of the total drug sales in hospitals, China's oncology market is outpacing the larger global market
Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research
SHANGHAI - Although anti-infective drugs still dominate China's pharma market with roughly one-fourth of the total drug sales in hospitals, China's oncology market is outpacing the larger global market
Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research
Three national surveys revealed that lung, liver, stomach and esophageal cancer were the top four killers in the last 30 years, accounting for roughly 70% of deaths from cancer in China.